N/A N=16 Effect of Exercise on the Human Skeletal Muscle Phosphoproteome
Skeletal Muscle Protein Synthesis
Primary: Change in Acute Muscle Protein Synthesis — 143; 123 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Impact of Muscle Temperature on Muscle Growth and Breakdown: Cooling During Resistance Training
Exercise Training
Primary: RT-qPCR for Forkhead Box O3 (FOXO3a) — 1.24; 1.30 fold change — p=.609
N/A N=61 Muscle Growth Following a Resistance Training Program in Men and Women Consuming Protein Supplements
Skeletal Muscle Growth
Primary: Lean Body Mass Change — 1.5; 1.3 kilogram — p=<0.05
N/A N=40 Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation
Osteoarthritis
Primary: Stair Time up — 7; 8 seconds
N/A N=68 Blood Flow, Muscle Regeneration and Sarcopenia
Sarcopenia
Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber
N/A N=38 Strength Training for Skeletal Muscle Adaptation After Stroke
Stroke
Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs
N/A N=141 Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults
Age-Related Sarcopenia · Muscle Loss
Primary: Double Leg Press Peak Power at 70% — 260.3; 255.6; 251.1; 264.8 Watts
N/A N=14 Muscle Capillarization and Sarcopenia
Sarcopenia
Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27
Phase 1 N=62 Muscle Perfusion and Protein Metabolism in Elderly
Aging
Primary: Mixed Muscle Fractional Synthesis Rate (FSR) — 0.061; 0.070; 0.066; 0.070 Fractional Synthesis Rate (pecent/hour)
N/A N=40 Muscle Mass During Space Exploration
Muscle Loss
Primary: Lean Leg Mass — -1.2; -0.9 g
Phase 3 N=28 Carnitine Supplementation and Skeletal Muscle Function
Sarcopenia
Primary: Blood Inflammatory Marker — 2.6; 1.8; 2.9; 1.7 mg·L^-1
Phase 1 N=32 Effect of a Ghrelin Receptor Agonist on Muscle and Bone
Sarcopenia · Osteopenia
Primary: Total Body Muscle Mass — 21.8; 20.8; 22.2; 20.8 kg units on a scale
N/A N=22 Regulation of Muscle Protein Phenotype in Humans With Obesity
Obesity
Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr
N/A N=33 Novel Intervention to Influence Muscle Plasticity in Veterans
Spinal Cord Injuries
Primary: HF Muscle Force — 23.9; 30.9 Newtons (N)
N/A N=16 Effect of an EAA/Whey Composition on Protein Metabolism
Sarcopenia
Primary: Protein Anabolism — 3.56; 11.8; 3.02 grams — p=<0.05
Phase 4 N=29 Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men
Sarcopenia
Primary: Serum Total Testosterone Measured Before Treatment on Treatment Day 1 (Baseline Study) — 307.57; 363.43; 408.17; 318.68 ng/dL
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
N/A N=18 Enhancing Skeletal Adaptations to PTH and Exercise
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=38 Training Induced Muscle Exosome Release
Metabolism
Primary: miR-1 Abundance — 226; 110; 286 percent change
N/A N=71 Musculoskeletal Plasticity After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001
Phase 2 N=20 Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears
Rupture of Anterior Cruciate Ligament
Primary: Normative Isokinetic Knee Extension Strength, Measured in Newton Meters (Nm) at 26 Weeks Post-op — 0.881; 0.681 Nm — p=0.0498
N/A N=44 Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
Sarcopenia · Aging · Immune Function
Primary: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine) — 63.1; 63.2 units per ml — p=>0.05
Phase 2 N=67 Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults
Muscle Atrophy · Quality of Life
Primary: MRI Quadriceps Involved Leg — 43.87; 38.31 AU — p=.03
N/A N=33 Training Effects on Skeletal Muscle Fatty Acid Metabolism
Healthy Volunteers
Primary: Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion — 8; 12; 6; 11 M value — p=<0.05
N/A N=15 Growth Hormone Treatment on Phosphocreatine Recovery in Obesity
Obese · Growth Hormone Secretion Abnormality
Primary: Phosphocreatine Recovery — 0.74 correlation coefficient — p=0.02
N/A N=80 Effect of Whey Protein Supplementation and Resistance Exercise on Muscle Parameters in Older Adults
Mobility Limitation
Primary: 1 Repetition Maximum Muscle Strength 1-RM (N) Double Leg Press — 1223; 1256; 1483; 1465 N
N/A N=33 Role of the Protein Matrix in the Anabolic Response to a Ground Beef Patty as Opposed to the Impossible (Vegi-) Burger
Protein Metabolism
Primary: Postprandial Plasma Essential Amino Acid Concentration Incremental Area-under-the-curve [ Time Frame: 360 Minutes] — 117896; 75098; 94058 micromoles per liter per minute
Phase 1 N=58 Phase 1 Study of ACE-083 in Healthy Subjects
Musculoskeletal Diseases
Primary: ACE-083 Safety and Tolerability: Number of Subjects With Adverse Events — 6; 6; 6; 6 Participants